| 摘要 |
In the present invention there are disclosed quinazoline derivatives of the general formula I (wherein Ye1 represents -O-, -S-, -CHi2-, -SO-, -SOi2-, -NRe5CO-, -CONRe6-, -SOi2NRe7-, -NRe8SOi2-, or -NRe9-, wherein Re5, Re6, Re7, Re8 and Re9 represent independently on each other hydrogen, alkyl or alkoxyalkyl; Re1 represents hydrogen, a hydroxyl group, a halogen, a nitro group, a trifluoromethyl group, a cyano group, an alkoxy group, an alkylthio group, an amino group or an alkylamino group; Re2 denotes hydrogen, a hydroxyl group, a halogen, an alkyl group, an alkoxyl group, a trifluoromethyl group, a cyano group, an amino group or a nitro group; m is an integer ranging from 1 up to 5; Re3 denotes a hydroxyl group, a halogen, an alkyl group, an alkoxyl group, an alkanoyloxy group, a trifluoromethyl group, a cyano group, an amino group or a nitro group; Re4 represents a group, which is or which contains an optionally substituted pyridone group, phenyl or an aromatic heterocyclic group) and salts thereof; a process for their preparing and pharmaceutical compositions containing the compound of the general formula I or pharmaceutically acceptable salts thereof as active component. The compounds of the general formula I and their pharmaceutically acceptable salts inhibit VEGF action, have valuable properties when treating many diseases, among others cancer and rheumatoid arthritis. |
